{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:55:10Z","timestamp":1793282110046,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CDC intramural funds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A long-acting injectable formulation of the HIV integrase inhibitor cabotegravir (CAB-LA) is currently in clinical development for PrEP. Although the long plasma half-life of CAB-LA is an important attribute for PrEP, it also raises concerns about drug resistance emergence if someone becomes infected with HIV, or if PrEP is initiated during undiagnosed acute infection. Here we use a macaque model of SHIV infection to model risks of drug resistance to CAB-LA PrEP. Six macaques infected with SHIV received CAB-LA before seroconversion. We show integrase mutations G118R, E92G\/Q, or G140R in plasma from 3\/6 macaques as early as day 57, and identify G118R and E92Q in viruses from vaginal and rectal fluids. G118R and G140R confer\u2009&gt;\u2009800-fold resistance to CAB and cross-resistance to all licensed integrase inhibitors. Our results emphasize the need for appropriate HIV testing strategies before and possibly shortly after initiating CAB LA PrEP to exclude acute infection.<\/jats:p>","DOI":"10.1038\/s41467-019-10047-w","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T06:02:54Z","timestamp":1556690574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection"],"prefix":"10.1038","volume":"10","author":[{"given":"Jessica","family":"Radzio-Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Council","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian-er","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ruone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xierong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanon","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Spreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Heneine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gerardo","family":"Garc\u00eda-Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"10047_CR1","unstructured":"World Health organization. HIV\/AIDS fact sheet World Health organization. http:\/\/www.who.int\/mediacentre\/factsheets\/fs360\/en\/ (2017)."},{"key":"10047_CR2","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2018.1917","volume":"319","author":"J Riddell","year":"2018","unstructured":"Riddell, J., Amico, K. R. & Mayer, K. H. HIV preexposure prophylaxis: a review. JAMA 319, 1261\u20131268 (2018).","journal-title":"JAMA"},{"key":"10047_CR3","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1097\/QAI.0000000000000469","volume":"68","author":"SL Karmon","year":"2015","unstructured":"Karmon, S. L., Mohri, H., Spreen, W. & Markowitz, M. GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. J. Acquir Immune Defic. Syndr. 68, e39\u2013e41 (2015).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10047_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/13543784.2018.1460357","volume":"27","author":"TD McPherson","year":"2018","unstructured":"McPherson, T. D., Sobieszczyk, M. E. & Markowitz, M. Cabotegravir in the treatment and prevention of human immunodeficiency virus-1. Expert Opin. Invest. Drugs 27, 413\u2013420 (2018).","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10047_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/COH.0000000000000168","volume":"10","author":"C Trezza","year":"2015","unstructured":"Trezza, C., Ford, S. L., Spreen, W., Pan, R. & Piscitelli, S. Formulation and pharmacology of long-acting cabotegravir. Curr. Opin. HIV Aids. 10, 239\u2013245 (2015).","journal-title":"Curr. Opin. HIV Aids."},{"key":"10047_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/QAI.0000000000000365","volume":"67","author":"W Spreen","year":"2014","unstructured":"Spreen, W. et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J. Acquir Immune Defic. Syndr. 67, 487\u2013492 (2014).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10047_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/COH.0000000000000002","volume":"8","author":"WR Spreen","year":"2013","unstructured":"Spreen, W. R., Margolis, D. A. & Pottage, J. C. Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr. Opin. HIV Aids. 8, 565\u2013571 (2013).","journal-title":"Curr. Opin. HIV Aids."},{"key":"10047_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1126\/science.1248707","volume":"343","author":"CD Andrews","year":"2014","unstructured":"Andrews, C. D. et al. Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus. Science 343, 1151\u20131154 (2014).","journal-title":"Science"},{"key":"10047_CR9","first-page":"270ra274","volume":"7","author":"CD Andrews","year":"2015","unstructured":"Andrews, C. D. et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci. Transl. Med. 7, 270ra274 (2015).","journal-title":"Sci. Transl. Med."},{"key":"10047_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/QAD.0000000000001343","volume":"31","author":"CD Andrews","year":"2017","unstructured":"Andrews, C. D. et al. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS 31, 461\u2013467 (2017).","journal-title":"AIDS"},{"key":"10047_CR11","doi-asserted-by":"publisher","first-page":"270ra275","DOI":"10.1126\/scitranslmed.3010297","volume":"7","author":"J Radzio","year":"2015","unstructured":"Radzio, J. et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci. Trans. Med. 7, 270ra275 (2015).","journal-title":"Sci. Trans. Med."},{"issue":"suppl 1","key":"10047_CR12","first-page":"83","volume":"26","author":"C Dobard","year":"2018","unstructured":"Dobard, C. et al. Long-acting cabotegravir protects macaques against repeated penile SHIV exposures. Top. Antivir. Med. 26(suppl 1), 83 (2018).","journal-title":"Top. Antivir. Med."},{"key":"10047_CR13","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","volume":"4","author":"M Markowitz","year":"2017","unstructured":"Markowitz, M. et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet Hiv. 4, e331\u2013e340 (2017).","journal-title":"Lancet Hiv."},{"key":"10047_CR14","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis, D. A. et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet 390, 1499\u20131510 (2017).","journal-title":"Lancet"},{"key":"10047_CR15","doi-asserted-by":"crossref","unstructured":"Margolis, D. A.et al. LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect. Dis. 15, 1145\u20131155 (2015).","DOI":"10.1016\/S1473-3099(15)00152-8"},{"key":"10047_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COH.0000000000000209","volume":"11","author":"UM Parikh","year":"2016","unstructured":"Parikh, U. M. & Mellors, J. W. Should we fear resistance from tenofovir\/emtricitabine preexposure prophylaxis? Curr. Opin. HIV AIDS 11, 49\u201355 (2016).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10047_CR17","doi-asserted-by":"publisher","first-page":"12002","DOI":"10.1128\/JVI.02131-15","volume":"89","author":"SA Hassounah","year":"2015","unstructured":"Hassounah, S. A. et al. Characterization of the drug resistance profiles of integrase strand transfer inhibitors in simianimmunodeficiency virus SIVmac239. J. Virol. 89, 12002\u201312013 (2015).","journal-title":"J. Virol."},{"key":"10047_CR18","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1128\/AAC.04829-14","volume":"59","author":"M Wares","year":"2015","unstructured":"Wares, M., Hassounah, S., Mespl\u00e8de, T., Sandstrom, P. A. & Wainberg, M. A. Simian-tropic HIV as a model to study drug resistance against integrase inhibitors. Antimicrob. Agents Chemother. 59, 1942\u20131949 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"10047_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-21","volume":"7","author":"MG Lewis","year":"2010","unstructured":"Lewis, M. G. et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 7, 21 (2010).","journal-title":"Retrovirology"},{"key":"10047_CR20","doi-asserted-by":"publisher","first-page":"9683","DOI":"10.1128\/JVI.00947-14","volume":"88","author":"SA Hassounah","year":"2014","unstructured":"Hassounah, S. A. et al. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J. Virol. 88, 9683\u20139692 (2014).","journal-title":"J. Virol."},{"key":"10047_CR21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi, M. et al. In vitro antiretroviral properties of S\/GSK1349572, a next generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55, 813\u2013821 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"10047_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.antiviral.2011.12.008","volume":"93","author":"NA Margot","year":"2012","unstructured":"Margot, N. A. et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antivir. Res. 93, 288\u2013296 (2012).","journal-title":"Antivir. Res."},{"key":"10047_CR23","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1128\/AAC.02568-12","volume":"57","author":"ME Abram","year":"2013","unstructured":"Abram, M. E. et al. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob. Agents Chemother. 57, 2654\u20132663 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"10047_CR24","doi-asserted-by":"publisher","first-page":"11440","DOI":"10.1128\/JVI.01168-09","volume":"83","author":"S Fransen","year":"2009","unstructured":"Fransen, S. et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83, 11440\u201311446 (2009).","journal-title":"J. Virol."},{"key":"10047_CR25","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/infdis\/jir636","volume":"204","author":"F Canducci","year":"2011","unstructured":"Canducci, F. et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J. Infect. Dis. 204, 1811\u20131815 (2011).","journal-title":"J. Infect. Dis."},{"key":"10047_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/QAI.0b013e31826bfd02","volume":"61","author":"MR Underwood","year":"2012","unstructured":"Underwood, M. R. et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J. Acquir. Immune Defic. Syndr. 61, 297\u2013301 (2012).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10047_CR27","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/JVI.03353-14","volume":"89","author":"PK Quashie","year":"2015","unstructured":"Quashie, P. K. et al. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J. Virol. 89, 3163\u20133175 (2015).","journal-title":"J. Virol."},{"key":"10047_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/infdis\/jiv528","volume":"213","author":"KJ Penrose","year":"2016","unstructured":"Penrose, K. J. et al. Selection of rilpivirine-resistant HIV-1 in a seroconverter from the SSAT 040 trial who received the 300-mg dose of long-acting rilpivirine (TMC278LA). J. Infect. Dis. 213, 1013\u20131017 (2016).","journal-title":"J. Infect. Dis."},{"key":"10047_CR29","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1128\/JVI.76.11.5803-5806.2002","volume":"76","author":"K Soderberg","year":"2002","unstructured":"Soderberg, K. et al. A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 76, 5803\u20135806 (2002).","journal-title":"J. Virol."},{"key":"10047_CR30","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.1128\/JVI.79.12.7349-7354.2005","volume":"79","author":"TW North","year":"2005","unstructured":"North, T. W. et al. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J. Virol. 79, 7349\u20137354 (2005).","journal-title":"J. Virol."},{"key":"10047_CR31","doi-asserted-by":"publisher","first-page":"8210","DOI":"10.1073\/pnas.92.18.8210","volume":"92","author":"K Uberla","year":"1995","unstructured":"Uberla, K. et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc. Natl Acad. Sci. USA 92, 8210\u20138214 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10047_CR32","doi-asserted-by":"publisher","first-page":"e50632","DOI":"10.1371\/journal.pone.0050632","volume":"7","author":"J Radzio","year":"2012","unstructured":"Radzio, J. et al. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS ONE 7, e50632 (2012).","journal-title":"PLoS ONE"},{"key":"10047_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-9-40","volume":"9","author":"Q Zheng","year":"2012","unstructured":"Zheng, Q., Ruone, S., Switzer, W. M., Heneine, W. & Garcia-Lerma, J. G. Limited SHIV env diversification in macaques failing oral antiretroviral pre-exposure prophylaxis. Retrovirology 9, 40 (2012).","journal-title":"Retrovirology"},{"key":"10047_CR34","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1093\/bioinformatics\/btp583","volume":"25","author":"IM Carr","year":"2009","unstructured":"Carr, I. M. et al. Inferring relative proportions of DNA variants from sequencing electropherograms. Bioinformatics 25, 3244\u20133250 (2009).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10047-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10047-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10047-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:06:52Z","timestamp":1671214012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10047-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["10047"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-10047-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]},"assertion":[{"value":"17 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.G.G-L. and W.H. are named in US. Government patents describing the use of a nucleoside and a nucleotide reverse transcriptase inhibitor for PrEP (Inhibition of HIV infection through chemoprophylaxis, patents No. 9044509B2, 9579333, and 9937191), and on a patent application on \u201cHIV Post-exposure Prophylaxis\u201d. C.J.P. is a Corporate Officer (Vice President) and shareholder of Laboratory Corporation of America (LabCorp), and the Chief Scientific Officer of Monogram Biosciences, a member of the LabCorp Specialty Testing Group. Monogram Biosciences\/LabCorp are for-profit providers of HIV drug resistance testing services that support routine diagnostic testing and the development of new antiviral drug candidates. We.H. and A.N. are employees and shareholders of Laboratory Corporation of America (LabCorp) and Monogram Biosciences. W.S. is an employee of ViiV Healthcare, the company who owns and is developing cabotegravir. The remaning authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2005"}}